Lipoprotein(a), a Lethal Player in Calcific Aortic Valve Disease

Area of Science:

• Cardiovascular Medicine
• Biochemistry
• Pharmacology

Background:

• Calcified aortic valve disease (CAVD) is the leading valvular heart disease, characterized by rising incidence and mortality.
• Current treatments for CAVD primarily involve valve replacement, with a significant unmet need for effective drug therapies.

Purpose of the Study:

• To elucidate the intricate relationship and underlying mechanisms between lipoprotein (a) (Lp(a)) and CAVD.
• To identify and review existing drugs with the potential to target Lp(a) for CAVD therapeutic strategies.

Main Methods:

• Comprehensive literature review of studies investigating Lp(a) in CAVD.
• Analysis of the pathophysiological roles of Lp(a) in endothelial dysfunction, inflammation, oxidative stress, and direct valve calcification.
• Evaluation of current pharmacological agents for their potential to reduce Lp(a) levels or mitigate its effects.

Main Results:

• Lipoprotein (a) (Lp(a)) is established as an independent risk factor for CAVD.
• Lp(a) contributes to CAVD by promoting endothelial dysfunction, foam cell formation via oxidized phospholipids (OxPL), inflammation, oxidative stress, and direct valve calcification.
• Clinical trials focusing on Lp(a) reduction as a primary endpoint are currently lacking.

Conclusions:

• Lipoprotein (a) (Lp(a)) plays a pivotal role in the pathogenesis of calcified aortic valve disease (CAVD).
• Targeting Lp(a) presents a promising therapeutic avenue for managing CAVD, addressing the current gap in drug treatment options.